Neurocrine Biosciences
NBIX
150.57
-6.02
-3.84%
Neurocrine Biosciences
US · NBIX
#1162 by market cap
Listed 1970
150.57
-6.02
-3.84%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Rating change
Guggenheim Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $224Market Newswire · 2026/11/4
-
Rating change
Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $220Benzinga · 2026/11/3
-
Company notice
Neurocrine Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer ROBERTS EIRYSEC · 2026/11/6
-
Company notice
Neurocrine Biosciences | 4: Statement of changes in beneficial ownership of securities-Director LYONS GARY ASEC · 2026/11/20
-
Revenue Beat: Neurocrine Biosciences, Inc. Exceeded Revenue Forecasts By 7.6% And Analysts Are Updating Their EstimatesSimply Wall St · 2026/11/5
-
Rating change
Deutsche Bank Raises Price Target on Neurocrine Biosciences to $175 From $165, Keeps Hold RatingMT Newswires · 2026/11/3
-
Rating change
RBC Lifts Price Target on Neurocrine Biosciences to $190 From $187, Keeps Outperform RatingMT Newswires · 2026/11/3
-
Neurocrine Biosciences Releases Findings From New Survey Showing Adults With Tardive Dyskinesia Reported Fewer Disruptions To Work, School After Starting Treatment With INGREZZA CapsulesBenzinga · 2026/11/5
-
Rating change
A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $175 to $230Market Newswire · 2026/11/4
-
Form 144 | Neurocrine Biosciences(NBIX.US) Insider Proposes to Sell 8.97 Million in Common StocksMarket Newswire · 2026/11/11
-
Company notice
Neurocrine Biosciences | 144: Notice of proposed sale of securities pursuant to Rule 144SEC · 2026/11/18
-
Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare ConferencePR Newswire · 2026/11/11
-
Rating change
Bernstein Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $218Market Newswire · 2026/11/5
-
Rating change
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $185Benzinga · 2026/11/4
-
Company notice
Neurocrine Biosciences | 144: Notice of proposed sale of securities pursuant to Rule 144SEC · 2026/11/11
-
Rating change
J.P. Morgan Maintains Neurocrine Biosciences(NBIX.US) With Buy RatingMarket Newswire · 2026/11/3
-
Rating change
Morgan Stanley Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Raises Target Price to $185Market Newswire · 2026/11/3
-
Rating change
Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $224Benzinga · 2026/11/4
-
Morgan Stanley Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Raises Target Price to $191Market Newswire · 2026/11/13
-
Company notice
Neurocrine Biosciences | 4: Statement of changes in beneficial ownership of securities-Director MORROW GEORGE JSEC · 2026/11/4
-
Rating change
Morgan Stanley Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Maintains Target Price $183Market Newswire · 2026/11/3
-
Company notice
Neurocrine Biosciences | 144: Notice of proposed sale of securities pursuant to Rule 144SEC · 2026/11/3
-
Rating change
Needham Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $204Market Newswire · 2026/10/16
-
Company notice
Neurocrine Biosciences | 8-K: Neurocrine Biosciences Reports Third-Quarter 2026 Financial ResultsSEC · 2026/11/3
-
Rating change
Wedbush Cuts Price Target on Neurocrine Biosciences to $186 From $194, Keeps Outperform RatingMT Newswires · 2026/10/19
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.
Neurocrine Biosciences discussion 0 comments